
FDA Drafts Guidance on Target Product Profiles and Issues 2007 Agenda
In March, the US Food and Drug Administration released a new draft guidance, along with its guidance agenda for the year.
In March, the US Food and Drug Administration released a new draft guidance, along with its guidance agenda for the year. The draft, “Guidance for Industry and Review Staff: Target Product Profile-A Strategic Development Process Tool,” is designed to provide sponsors and the review staff in the Center for Drug Evaluation and Research (CDER) with information regarding target product profiles (TPPs).
A TPP is a format for a summary of a drug development program described in terms of labeling concepts. A TPP can be prepared by a sponsor and then shared with the appropriate FDA review staff to facilitate communication regarding a particular drug development program. Submission of a TPP is voluntary. The guidance describes the purpose of a TPP, its advantages, and its optimal use. It also provides guidance on how to complete a TPP and relates case studies that demonstrate a TPP’s usefulness.
The
CDER has also released its guidance agenda for the year 2007. The plan includes a guidance on quality by design and the long-awaited guidance for process validation, which would update the 1987 process validation guidelines. The complete agenda can be found at:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.